A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants

Exclusion Criteria

• •1. Preterm birth (delivery before the 37th week of pregnancy).
• •2. Previous vaccination against polio.
• •3. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
• •4. History of polio.
• •5. History or family history of convulsions, seizures, encephalopathy, and neurological disorder.
• •6. History of a serious reaction to any prior vaccination or known hypersensitivity to any component of the investigational vaccine.
• •7. Individuals with immunodeficiency or receiving immunosuppression therapy.
• •8. Disturbance of coagulation diagnosed by doctor (e.g., coagulation factors deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder.
• •9. Known or suspected concomitant diseases include: respiratory disease, acute infection or active chronic disease, cardiovascular disease, liver and kidney disease, skin disease, mother with HIV infection.
• •10. Administration of blood or blood-related products or immunoglobulins (hepatitis B immunoglobulins is acceptable).
• •11. History of administration of live attenuated vaccines within 14 days.
• •12. History of administration of subunit or inactivated vaccines within 7 days.
• •13. Individuals with any acute diseases within 7 days, receiving antibiotics or antiviral therapy.
• •14. Fever within 3 days (Armpit temperature ≥38.0 ℃).
• •15. Use of any investigational product recently, or have any conditions that the investigator believes may affect the evaluation of the trial.